OMERS ADMINISTRATION Corp Acquires Shares of 15,911 Insulet Corporation $PODD

Key Points

• OMERS Administration initiated a position in Insulet by purchasing 15,911 shares valued at approximately $2.42 million. Other major investors, including BlackRock and Norges Bank, also recently established or expanded significant holdings.
• Insulet reported quarterly adjusted EPS of $1.66 and revenue of $801.7 million, exceeding estimates, while revenue increased 23.5% year over year. However, analysts have sharply reduced price targets, and the consensus rating remains “Hold” with an average target of $195.40.
• Insulet faces increased legal and reputational risk after securities class-action allegations related to manufacturing deficiencies and recalls involving Omnipod devices. The allegations have not been proven, while insider purchases—including by a director and the CEO—may signal management confidence after the stock’s steep decline.

OMERS ADMINISTRATION Corp bought a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,911 shares of the medical instruments supplier's stock, valued at approximately $2,422,000.

A number of other large investors have also recently made changes to their positions in PODD. BlackRock Inc. purchased a new position in shares of Insulet during the second quarter worth approximately $1,018,582,000. Norges Bank bought a new stake in shares of Insulet during the fourth quarter valued at approximately $300,794,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Insulet in the second quarter valued at approximately $60,615,000. Finally, Deutsche Bank AG bought a new position in Insulet in the second quarter worth approximately $51,153,000.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business's stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company's stock.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet CEO Ashley McEvoy purchased 1,100 shares at an average price of $147.47, an investment of approximately $162,200. The purchase increased her direct holdings by about 5% and may signal management confidence following the stock’s substantial decline. Insulet CEO share purchase
• Positive Sentiment: Recent operating results remain a support: Insulet’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 23.5% year over year and margins improving. The company’s growth outlook, however, has been reset, making execution key to the investment case.
• Neutral Sentiment: Reported short-interest data shows zero shares short and a zero-day short-interest ratio, but the stated month-over-month change is “NaN,” indicating the data is likely incomplete or erroneous. It should not be interpreted as evidence of a meaningful short-covering or short-selling trend.
• Negative Sentiment: Pomerantz announced that a securities class action has been filed in federal court against Insulet and certain officers. The proposed class covers investors who purchased securities from February 21, 2025, through May 26, 2026, and alleges violations of federal securities laws. The allegations have not been proven. Pomerantz class action announcement
• Negative Sentiment: Several firms issued substantially similar notices encouraging investors to seek lead-plaintiff status by August 31. The claims center on alleged manufacturing deficiencies and two voluntary corrections or recalls affecting millions of Omnipod devices, as well as assertions that Insulet overstated manufacturing quality and growth prospects. The volume of legal announcements increases reputational, litigation-cost, and potential-liability concerns, even though the notices themselves do not establish wrongdoing.

Insulet Stock Down 1.6%

Shares of NASDAQ PODD opened at $143.05 on Wednesday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The stock's fifty day simple moving average is $154.52 and its two-hundred day simple moving average is $182.80. The stock has a market capitalization of $9.92 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 1.15 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the topic of several research reports. Canaccord Genuity Group reduced their price objective on Insulet from $249.00 to $179.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $152.00 price target (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Jefferies Financial Group cut their price target on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Sanford C. Bernstein decreased their price objective on Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Finally, Truist Financial reiterated a "hold" rating and set a $153.00 target price (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of "Hold" and an average price target of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source